<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01688921</url>
  </required_header>
  <id_info>
    <org_study_id>PJ-501-12-2</org_study_id>
    <nct_id>NCT01688921</nct_id>
  </id_info>
  <brief_title>Jet Injection for Influenza</brief_title>
  <acronym>JIFI</acronym>
  <official_title>Jet Injection for Influenza: A Randomized Controlled Clinical Trial to Demonstrate Non Inferiority of Jet Injection vs. Needle and Syringe for Administration of Trivalent Inactivated Influenza Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaJet, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaJet, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the administration of a seasonal flu vaccine
      using a PharmaJet's needle-free injection device (STRATIS) is equivalent to needle and
      syringe administration, as measured by laboratory tests of immune response.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti Influenza Type A/H1N1 Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT)</measure>
    <time_frame>28 days</time_frame>
    <description>The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio(GMT with NS / GMT with PJ Stratis) for A/H1N1 antigen will not exceed 1.5 fold.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti Influenza Type A/H2N3 Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT)</measure>
    <time_frame>28 days</time_frame>
    <description>The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio(GMT with NS / GMT with PJ Stratis) for each antigen to not exceed 1.5 fold.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti Influenza Type B Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT)</measure>
    <time_frame>28 days</time_frame>
    <description>The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio(GMT with NS / GMT with PJ Stratis) for each antigen to not exceed 1.5 fold.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti Influenza Type A/H1N1 Seroconversion</measure>
    <time_frame>28 days</time_frame>
    <description>Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (&lt;1:10), attainment of a post-immunization titer of ≥1:40.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti Influenza Type A/H3N2 Seroconversion</measure>
    <time_frame>28 days</time_frame>
    <description>Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (&lt;1:10), attainment of a post-immunization titer of ≥1:40.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti Influenza Type B Seroconversion</measure>
    <time_frame>28 days</time_frame>
    <description>Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (&lt;1:10), attainment of a post-immunization titer of ≥1:40.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Complaints Within 30 Minutes Following Vaccination</measure>
    <time_frame>Within 30 minutes post-vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Vaccine Reactogenicity Events</measure>
    <time_frame>Day 0, 1, 2, 3, 4, 5, and 6</time_frame>
    <description>Vaccine reactogenicity will be collected on a patient-completed diary card during checkout from Day 0 and on the next six evenings post-vaccination. The following adverse events will be solicited on the diary card: pain at injection site, tenderness at injection site, redness where the injection is given; induration/swelling (lump) where the injection is given; bruising where the injection is given; itching where the injection is given; headache; tiredness/fatigue (asthenia, lethargy, malaise); general muscle ache (myalgia); chills; nausea; vomiting. Subjects will also record their oral temperature on the diary card each evening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Spontaneously Reported Adverse Events</measure>
    <time_frame>28 days</time_frame>
    <description>Subjects will be asked to report any other symptoms experienced in addition to the solicited &quot;immediate&quot; and &quot;vaccine reactogenicity&quot; events. Any other events reported will be tabulated as spontaneously reported adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Who Received a PJ Stratis Injection Would Choose to Receive This Type of Injection Again</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1250</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>STRATIS Needle-Free</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to this arm will receive AFLURIA vaccine administered using the Stratis needle-free injection device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Needle-Syringe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients assigned to this arm will receive AFLURIA vaccine administered using a needle and syringe.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AFLURIA vaccine (2012-2013 formulation)</intervention_name>
    <description>Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.</description>
    <arm_group_label>STRATIS Needle-Free</arm_group_label>
    <arm_group_label>Needle-Syringe</arm_group_label>
    <other_name>trivalent inactivated influenza vaccine (TIV)</other_name>
    <other_name>influenza virus vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Needle-Syringe</intervention_name>
    <arm_group_label>STRATIS Needle-Free</arm_group_label>
    <arm_group_label>Needle-Syringe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stratis needle-free injection device</intervention_name>
    <arm_group_label>STRATIS Needle-Free</arm_group_label>
    <arm_group_label>Needle-Syringe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged ≥18 and ≤64 years of age at the time of enrollment

          -  Willing and able to give informed consent after reading the consent form and adequate
             opportunity to discuss the study with the investigator or qualified designee

          -  Willing and able to adhere to all protocol required study procedures and to attend
             scheduled visits.

          -  Able to receive the TIV influenza vaccine, based on University of Colorado Health
             (UCH) employee health flu screening guidelines.

          -  Stable health status with no exclusionary medical or neuropsychiatric conditions as
             determined during the screening evaluation and based on the clinical judgment of the
             investigator or qualified designee.

          -  Access to a consistent means of telephone contact

        Exclusion Criteria:

          -  Presence of any febrile illness (oral temperature &gt;38°C) on the day of immunization.
             Such subjects will be reevaluated for enrollment after resolution of illness.

          -  Presence of significant acute or chronic uncontrolled medical or neuropsychiatric
             illness and /or presence of any significant condition that may prohibit inclusion as
             determined by the investigator or his qualified designee. Uncontrolled is defined as:
             requiring institution of a new treatment within 1 month prior to study enrollment or
             change in medication dosage in the month prior to study enrollment.

          -  Any immunosuppressive condition including: history of HIV infection, cancer or cancer
             treatment within 3 years of study enrollment, systemic glucocorticoids (in a dose ≥10
             mg prednisone daily or equivalent for more than 7 consecutive days or for 10 or more
             days in total) within 1 month of study enrollment, or any other cytotoxic or
             immunosuppressive drug within 3 months of study enrollment. Any significant disorder
             of coagulation that would increase the risk of intramuscular injections or treatment
             with Coumadin derivatives or heparin.

          -  Known or suspected to be allergic to eggs, chicken protein, gentamicin or influenza
             vaccine.

          -  History of severe or previous serious adverse reaction after an influenza vaccination.

          -  Receipt of any immunoglobulin and/or blood products within 3 months of immunization or
             planned administration of any of these products during the study period.

          -  Prior history of any demyelinating disease including Guillain-Barre syndrome.

          -  Presence of an active neurological disorder.

          -  History of significant alcohol or drug abuse within one year prior to study
             enrollment.

          -  Influenza vaccination or laboratory confirmed influenza infection within the previous
             six months before study vaccination or planned influenza vaccination during the study
             period.

          -  Planned administration of any non-influenza vaccines 30 days prior to the study or
             during the study period.

          -  Pregnant or plans to become pregnant during the study period.

          -  Currently enrolled in another vaccine or drug study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David K Cobb, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rocky Mountain Infectious Disease Consultants</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linda McAllister, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>PharmaJet, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Poudre Valley Hospital</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80524</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Harmony Campus</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of the Rockies</name>
      <address>
        <city>Loveland</city>
        <state>Colorado</state>
        <zip>80538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2012</study_first_submitted>
  <study_first_submitted_qc>September 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2012</study_first_posted>
  <results_first_submitted>September 15, 2014</results_first_submitted>
  <results_first_submitted_qc>October 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 22, 2014</results_first_posted>
  <disposition_first_submitted>March 5, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>March 5, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 14, 2013</disposition_first_posted>
  <last_update_submitted>September 29, 2017</last_update_submitted>
  <last_update_submitted_qc>September 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Injections, Jet</keyword>
  <keyword>Influenza Vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>STRATIS</title>
          <description>Patients assigned to this arm will receive AFLURIA vaccine administered using the STRATIS needle-free injection device.
AFLURIA vaccine (2012-2013 formulation): Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
STRATIS needle-free injection device</description>
        </group>
        <group group_id="P2">
          <title>Needle-Syringe</title>
          <description>Patients assigned to this arm will receive AFLURIA vaccine administered using a needle and syringe.
AFLURIA vaccine (2012-2013 formulation): Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
Needle-Syringe</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="627"/>
                <participants group_id="P2" count="623"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="611"/>
                <participants group_id="P2" count="608"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>informed consent</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Three subjects randomized to the PJ Stratis arm did not have properly documented informed consent and were excluded from the Full Analysis Set (FAS).</population>
      <group_list>
        <group group_id="B1">
          <title>STRATIS</title>
          <description>Patients assigned to this arm will receive AFLURIA vaccine administered using the STRATIS needle-free injection device.
AFLURIA vaccine (2012-2013 formulation): Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
STRATIS needle-free injection device</description>
        </group>
        <group group_id="B2">
          <title>Needle-Syringe</title>
          <description>Patients assigned to this arm will receive AFLURIA vaccine administered using a needle and syringe.
AFLURIA vaccine (2012-2013 formulation): Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
Needle-Syringe</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="624"/>
            <count group_id="B2" value="623"/>
            <count group_id="B3" value="1247"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.3" spread="12.92"/>
                    <measurement group_id="B2" value="41.5" spread="12.49"/>
                    <measurement group_id="B3" value="41.4" spread="12.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="624"/>
                    <measurement group_id="B2" value="623"/>
                    <measurement group_id="B3" value="1247"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="449"/>
                    <measurement group_id="B2" value="432"/>
                    <measurement group_id="B3" value="881"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="175"/>
                    <measurement group_id="B2" value="191"/>
                    <measurement group_id="B3" value="366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="624"/>
                    <measurement group_id="B2" value="623"/>
                    <measurement group_id="B3" value="1247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anti Influenza Type A/H1N1 Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT)</title>
        <description>The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio(GMT with NS / GMT with PJ Stratis) for A/H1N1 antigen will not exceed 1.5 fold.</description>
        <time_frame>28 days</time_frame>
        <population>The immunogenicity analyses were conducted using data from subjects in the Immunogenicity Population.</population>
        <group_list>
          <group group_id="O1">
            <title>PJ STRATIS</title>
            <description>Patients assigned to this arm will receive AFLURIA vaccine administered using the PJ STRATIS needle-free injection device.
AFLURIA vaccine (2012-2013 formulation): Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
PJ STRATIS needle-free injection device</description>
          </group>
          <group group_id="O2">
            <title>Needle-Syringe</title>
            <description>Patients assigned to this arm will receive AFLURIA vaccine administered using a needle and syringe.
AFLURIA vaccine (2012-2013 formulation): Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
Needle-Syringe</description>
          </group>
        </group_list>
        <measure>
          <title>Anti Influenza Type A/H1N1 Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT)</title>
          <description>The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio(GMT with NS / GMT with PJ Stratis) for A/H1N1 antigen will not exceed 1.5 fold.</description>
          <population>The immunogenicity analyses were conducted using data from subjects in the Immunogenicity Population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="562"/>
                <count group_id="O2" value="568"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.43" spread="1.348"/>
                    <measurement group_id="O2" value="4.38" spread="1.352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.64" spread="1.006"/>
                    <measurement group_id="O2" value="5.64" spread="0.997"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For a sample size of 550 per group each test has an individual power of &gt; 99% to rule out the 1.5-fold difference using a two-sided α = 0.05, assuming equal GMTs between the two treatment groups. The overall power for the study to demonstrate the non-inferiority for the 6 co-primary endpoints is &gt; 80%, computed as product of 6 individual powers.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin was defined as the upper bound of the two-sided 95% CI of the GMT ratio (GMT with NS / GMT with PJ Stratis) for each antigen did not exceed 1.5 fold.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti Influenza Type A/H2N3 Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT)</title>
        <description>The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio(GMT with NS / GMT with PJ Stratis) for each antigen to not exceed 1.5 fold.</description>
        <time_frame>28 days</time_frame>
        <population>The immunogenicity analyses were conducted using data from subjects in the Immunogenicity Population.</population>
        <group_list>
          <group group_id="O1">
            <title>PJ STRATIS</title>
            <description>Patients assigned to this arm will receive AFLURIA vaccine administered using the STRATIS needle-free injection device.
AFLURIA vaccine (2012-2013 formulation): Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
PJ STRATIS needle-free injection device</description>
          </group>
          <group group_id="O2">
            <title>Needle-Syringe</title>
            <description>Patients assigned to this arm will receive AFLURIA vaccine administered using a needle and syringe.
AFLURIA vaccine (2012-2013 formulation): Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
Needle-Syringe</description>
          </group>
        </group_list>
        <measure>
          <title>Anti Influenza Type A/H2N3 Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT)</title>
          <description>The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio(GMT with NS / GMT with PJ Stratis) for each antigen to not exceed 1.5 fold.</description>
          <population>The immunogenicity analyses were conducted using data from subjects in the Immunogenicity Population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="562"/>
                <count group_id="O2" value="568"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.22" spread="1.283"/>
                    <measurement group_id="O2" value="4.32" spread="1.290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.51" spread="1.022"/>
                    <measurement group_id="O2" value="5.58" spread="0.987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For a sample size of 550 per group each test has an individual power of &gt; 99% to rule out the 1.5-fold difference using a two-sided α = 0.05, assuming equal GMTs between the two treatment groups. The overall power for the study to demonstrate the non-inferiority for the 6 co-primary endpoints is &gt; 80%, computed as product of 6 individual powers.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin was defined as the upper bound of the two-sided 95% CI of the GMT ratio (GMT with NS / GMT with PJ Stratis) for each antigen did not exceed 1.5 fold.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti Influenza Type B Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT)</title>
        <description>The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio(GMT with NS / GMT with PJ Stratis) for each antigen to not exceed 1.5 fold.</description>
        <time_frame>28 days</time_frame>
        <population>The immunogenicity analyses were conducted using data from subjects in the Immunogenicity Population.</population>
        <group_list>
          <group group_id="O1">
            <title>PJ STRATIS</title>
            <description>Patients assigned to this arm will receive AFLURIA vaccine administered using the STRATIS needle-free injection device.
AFLURIA vaccine (2012-2013 formulation): Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
PJ STRATIS needle-free injection device</description>
          </group>
          <group group_id="O2">
            <title>Needle-Syringe</title>
            <description>Patients assigned to this arm will receive AFLURIA vaccine administered using a needle and syringe.
AFLURIA vaccine (2012-2013 formulation): Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
Needle-Syringe</description>
          </group>
        </group_list>
        <measure>
          <title>Anti Influenza Type B Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT)</title>
          <description>The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio(GMT with NS / GMT with PJ Stratis) for each antigen to not exceed 1.5 fold.</description>
          <population>The immunogenicity analyses were conducted using data from subjects in the Immunogenicity Population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="562"/>
                <count group_id="O2" value="568"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.60" spread="1.028"/>
                    <measurement group_id="O2" value="2.54" spread="1.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.75" spread="1.037"/>
                    <measurement group_id="O2" value="3.68" spread="1.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For a sample size of 550 per group each test has an individual power of &gt; 99% to rule out the 1.5-fold difference using a two-sided α = 0.05, assuming equal GMTs between the two treatment groups. The overall power for the study to demonstrate the non-inferiority for the 6 co-primary endpoints is &gt; 80%, computed as product of 6 individual powers.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin was defined as the upper bound of the two-sided 95% CI of the GMT ratio (GMT with NS / GMT with PJ Stratis) for each antigen did not exceed 1.5 fold.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti Influenza Type A/H1N1 Seroconversion</title>
        <description>Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (&lt;1:10), attainment of a post-immunization titer of ≥1:40.</description>
        <time_frame>28 days</time_frame>
        <population>The immunogenicity analyses were conducted using data from subjects in the Immunogenicity Population.</population>
        <group_list>
          <group group_id="O1">
            <title>PJ STRATIS</title>
            <description>Patients assigned to this arm will receive AFLURIA vaccine administered using the STRATIS needle-free injection device.
AFLURIA vaccine (2012-2013 formulation): Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
PJ STRATIS needle-free injection device</description>
          </group>
          <group group_id="O2">
            <title>Needle-Syringe</title>
            <description>Patients assigned to this arm will receive AFLURIA vaccine administered using a needle and syringe.
AFLURIA vaccine (2012-2013 formulation): Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
Needle-Syringe</description>
          </group>
        </group_list>
        <measure>
          <title>Anti Influenza Type A/H1N1 Seroconversion</title>
          <description>Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (&lt;1:10), attainment of a post-immunization titer of ≥1:40.</description>
          <population>The immunogenicity analyses were conducted using data from subjects in the Immunogenicity Population.</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="562"/>
                <count group_id="O2" value="568"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="38.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For a sample size of 550 per group each test has an individual power of &gt; 95% to rule out the 10 percentage points difference using a one-sided α = 0.025, assuming equal seroconversion rates between the two treatment groups. The overall power for the study to demonstrate the non-inferiority for the 6 co-primary endpoints is &gt; 80%, computed as product of 6 individual powers.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Seroconversion rate defined as the proportion of subjects with either a pre-vaccination titer of &lt;10 achieving a post-vaccination antibody of HI titer of ≥ 40 or with a pre-vaccination HI titer of ≥ 10 achieving a four-fold or greater increase in post-vaccination HI titer. The non-inferiority margin was defined as the upper bound of the two-sided 95% CI on the difference between the seroconversion rates (rate with NS - with PJ Stratis) for each vaccine strain did not exceed 10 percentage points.</non_inferiority_desc>
            <param_type>Seroconversion Rate Difference</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.8</ci_lower_limit>
            <ci_upper_limit>6.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti Influenza Type A/H3N2 Seroconversion</title>
        <description>Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (&lt;1:10), attainment of a post-immunization titer of ≥1:40.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PJ STRATIS</title>
            <description>Patients assigned to this arm will receive AFLURIA vaccine administered using the STRATIS needle-free injection device.
AFLURIA vaccine (2012-2013 formulation): Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
PJ STRATIS needle-free injection device</description>
          </group>
          <group group_id="O2">
            <title>Needle-Syringe</title>
            <description>Patients assigned to this arm will receive AFLURIA vaccine administered using a needle and syringe.
AFLURIA vaccine (2012-2013 formulation): Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
Needle-Syringe</description>
          </group>
        </group_list>
        <measure>
          <title>Anti Influenza Type A/H3N2 Seroconversion</title>
          <description>Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (&lt;1:10), attainment of a post-immunization titer of ≥1:40.</description>
          <units>Percent of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="562"/>
                <count group_id="O2" value="568"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8"/>
                    <measurement group_id="O2" value="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For a sample size of 550 per group each test has an individual power of &gt; 95% to rule out the 10 percentage points difference using a one-sided α = 0.025, assuming equal seroconversion rates between the two treatment groups. The overall power for the study to demonstrate the non-inferiority for the 6 co-primary endpoints is &gt; 80%, computed as product of 6 individual powers.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Seroconversion rate defined as the proportion of subjects with either a pre-vaccination titer of &lt;10 achieving a post-vaccination antibody of HI titer of ≥ 40 or with a pre-vaccination HI titer of ≥ 10 achieving a four-fold or greater increase in post-vaccination HI titer. The non-inferiority margin was defined as the upper bound of the two-sided 95% CI on the difference between the seroconversion rates(rate with NS - with PJ Stratis) for each vaccine strain did not exceed 10 percentage points</non_inferiority_desc>
            <param_type>Seroconversion Rate Difference</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.5</ci_lower_limit>
            <ci_upper_limit>7.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti Influenza Type B Seroconversion</title>
        <description>Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (&lt;1:10), attainment of a post-immunization titer of ≥1:40.</description>
        <time_frame>28 days</time_frame>
        <population>The immunogenicity analyses were conducted using data from subjects in the Immunogenicity Population.</population>
        <group_list>
          <group group_id="O1">
            <title>PJ STRATIS</title>
            <description>Patients assigned to this arm will receive AFLURIA vaccine administered using the STRATIS needle-free injection device.
AFLURIA vaccine (2012-2013 formulation): Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
PJ STRATIS needle-free injection device</description>
          </group>
          <group group_id="O2">
            <title>Needle-Syringe</title>
            <description>Patients assigned to this arm will receive AFLURIA vaccine administered using a needle and syringe.
AFLURIA vaccine (2012-2013 formulation): Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
Needle-Syringe</description>
          </group>
        </group_list>
        <measure>
          <title>Anti Influenza Type B Seroconversion</title>
          <description>Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (&lt;1:10), attainment of a post-immunization titer of ≥1:40.</description>
          <population>The immunogenicity analyses were conducted using data from subjects in the Immunogenicity Population.</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="562"/>
                <count group_id="O2" value="568"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9"/>
                    <measurement group_id="O2" value="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For a sample size of 550 per group each test has an individual power of &gt; 91% to rule out the 10 percentage points difference using a one-sided α = 0.025, assuming equal seroconversion rates between the two treatment groups. The overall power for the study to demonstrate the non-inferiority for the 6 co-primary endpoints is &gt; 80%, computed as product of 6 individual powers.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Seroconversion rate was defined as the proportion of subjects with either a pre-vaccination titer of &lt;10 achieving a post-vaccination antibody of HI titer of ≥ 40 or with a pre-vaccination HI titer of ≥ 10 achieving a four-fold or greater increase in post-vaccination HI titer.
The upper-bound of the two-sided 95% CI on the difference in seroconversion rates for the A/H1N1, A/H3N2, and B strains did not exceed 10 percentage points (6.5, 7.1, and 5.9 respectively).</non_inferiority_desc>
            <param_type>Seroconversion Rate Difference</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.2</ci_lower_limit>
            <ci_upper_limit>5.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Complaints Within 30 Minutes Following Vaccination</title>
        <time_frame>Within 30 minutes post-vaccination</time_frame>
        <population>The safety population included 1247 subjects (N=624 PJ Stratis, N=623 NS).</population>
        <group_list>
          <group group_id="O1">
            <title>PJ STRATIS</title>
            <description>Patients assigned to this arm will receive AFLURIA vaccine administered using the STRATIS needle-free injection device.
AFLURIA vaccine (2012-2013 formulation): Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
PJ STRATIS needle-free injection device</description>
          </group>
          <group group_id="O2">
            <title>Needle-Syringe</title>
            <description>Patients assigned to this arm will receive AFLURIA vaccine administered using a needle and syringe.
AFLURIA vaccine (2012-2013 formulation): Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
Needle-Syringe</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Complaints Within 30 Minutes Following Vaccination</title>
          <population>The safety population included 1247 subjects (N=624 PJ Stratis, N=623 NS).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="624"/>
                <count group_id="O2" value="623"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bruising</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Immediate adverse events were reported within 30 minutes of receiving the vaccination; therefore, they are all considered related to study treatment.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Vaccine Reactogenicity Events</title>
        <description>Vaccine reactogenicity will be collected on a patient-completed diary card during checkout from Day 0 and on the next six evenings post-vaccination. The following adverse events will be solicited on the diary card: pain at injection site, tenderness at injection site, redness where the injection is given; induration/swelling (lump) where the injection is given; bruising where the injection is given; itching where the injection is given; headache; tiredness/fatigue (asthenia, lethargy, malaise); general muscle ache (myalgia); chills; nausea; vomiting. Subjects will also record their oral temperature on the diary card each evening.</description>
        <time_frame>Day 0, 1, 2, 3, 4, 5, and 6</time_frame>
        <population>The safety population included 1247 subjects (N=624 PJ Stratis, N=623 NS). Eight subjects (624-616) in the PJ Stratis group and 16 (623-607) in the NS group did not return the 7-Day Diary Card.</population>
        <group_list>
          <group group_id="O1">
            <title>PJ STRATIS</title>
            <description>Patients assigned to this arm will receive AFLURIA vaccine administered using the STRATIS needle-free injection device.
AFLURIA vaccine (2012-2013 formulation): Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
PJ STRATIS needle-free injection device</description>
          </group>
          <group group_id="O2">
            <title>Needle-Syringe</title>
            <description>Patients assigned to this arm will receive AFLURIA vaccine administered using a needle and syringe.
AFLURIA vaccine (2012-2013 formulation): Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
Needle-Syringe</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Vaccine Reactogenicity Events</title>
          <description>Vaccine reactogenicity will be collected on a patient-completed diary card during checkout from Day 0 and on the next six evenings post-vaccination. The following adverse events will be solicited on the diary card: pain at injection site, tenderness at injection site, redness where the injection is given; induration/swelling (lump) where the injection is given; bruising where the injection is given; itching where the injection is given; headache; tiredness/fatigue (asthenia, lethargy, malaise); general muscle ache (myalgia); chills; nausea; vomiting. Subjects will also record their oral temperature on the diary card each evening.</description>
          <population>The safety population included 1247 subjects (N=624 PJ Stratis, N=623 NS). Eight subjects (624-616) in the PJ Stratis group and 16 (623-607) in the NS group did not return the 7-Day Diary Card.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="616"/>
                <count group_id="O2" value="607"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="397"/>
                    <measurement group_id="O2" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="551"/>
                    <measurement group_id="O2" value="472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="366"/>
                    <measurement group_id="O2" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="392"/>
                    <measurement group_id="O2" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bruising</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191"/>
                    <measurement group_id="O2" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222"/>
                    <measurement group_id="O2" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The safety population included subjects who received the vaccination and for whom follow-up data were available for a specific safety analysis. Therefore, the denominators for different safety tables vary, depending on the availability of the data.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Spontaneously Reported Adverse Events</title>
        <description>Subjects will be asked to report any other symptoms experienced in addition to the solicited &quot;immediate&quot; and &quot;vaccine reactogenicity&quot; events. Any other events reported will be tabulated as spontaneously reported adverse events.</description>
        <time_frame>28 days</time_frame>
        <population>The safety population included 1247 subjects (N=624 PJ Stratis, N=623 NS).</population>
        <group_list>
          <group group_id="O1">
            <title>PJ STRATIS</title>
            <description>Patients assigned to this arm will receive AFLURIA vaccine administered using the STRATIS needle-free injection device.
AFLURIA vaccine (2012-2013 formulation): Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
PJ STRATIS needle-free injection device</description>
          </group>
          <group group_id="O2">
            <title>Needle-Syringe</title>
            <description>Patients assigned to this arm will receive AFLURIA vaccine administered using a needle and syringe.
AFLURIA vaccine (2012-2013 formulation): Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
Needle-Syringe</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Spontaneously Reported Adverse Events</title>
          <description>Subjects will be asked to report any other symptoms experienced in addition to the solicited &quot;immediate&quot; and &quot;vaccine reactogenicity&quot; events. Any other events reported will be tabulated as spontaneously reported adverse events.</description>
          <population>The safety population included 1247 subjects (N=624 PJ Stratis, N=623 NS).</population>
          <units>participants with spontaneous AEs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="624"/>
                <count group_id="O2" value="623"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Who Received a PJ Stratis Injection Would Choose to Receive This Type of Injection Again</title>
        <time_frame>28 Days</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>PJ STRATIS</title>
            <description>Patients assigned to this arm will receive AFLURIA vaccine administered using the PJ STRATIS needle-free injection device.
AFLURIA vaccine (2012-2013 formulation): Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
PJ STRATIS needle-free injection device</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Received a PJ Stratis Injection Would Choose to Receive This Type of Injection Again</title>
          <population>Safety population</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="624"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Immediate complaints were solicited from subjects in the safety population following vaccination: pain, tenderness, itching, redness, swelling, and bruising at the vaccination site.</time_frame>
      <desc>Solicited adverse events were those events specifically sought for and recorded by the subject in the 7-Day Diary Card.
The denominators were determined for each individual AE for each summary window (Day 0-3 or 4-6). Subjects in Safety Populations were excluded from the denominator if there was no data captured for the AE within summary window.</desc>
      <group_list>
        <group group_id="E1">
          <title>STRATIS</title>
          <description>Patients assigned to this arm will receive AFLURIA vaccine administered using the STRATIS needle-free injection device.
AFLURIA vaccine (2012-2013 formulation): Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
STRATIS needle-free injection device</description>
        </group>
        <group group_id="E2">
          <title>Needle-Syringe</title>
          <description>Patients assigned to this arm will receive AFLURIA vaccine administered using a needle and syringe.
AFLURIA vaccine (2012-2013 formulation): Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
Needle-Syringe</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="624"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="623"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <description>The SAE reported was unrelated to the subject's participation in the study.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="624"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="623"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <description>The SAE reported was unrelated to the subject's participation in the study.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="624"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="623"/>
              </event>
              <event>
                <sub_title>Arterial Injury</sub_title>
                <description>The SAE reported was unrelated to the subject's participation in the study.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="624"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="623"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal Ulcer Perforation</sub_title>
                <description>The SAE was unrelated to subject's participation in the study.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="624"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="623"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Peritonitis</sub_title>
                <description>The SAE reported was unrelated to subject's participation in the study.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="624"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="623"/>
              </event>
              <event>
                <sub_title>Viral Meningitis</sub_title>
                <description>The SAE reported was unrelated to the subject's participation in the study.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="624"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="623"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="586" subjects_at_risk="624"/>
                <counts group_id="E2" subjects_affected="516" subjects_at_risk="623"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="610"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>Local symptoms at injection site within 6 days of vaccination with Grade of &gt;=1</description>
                <counts group_id="E1" subjects_affected="397" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="299" subjects_at_risk="606"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <description>Local Adverse Reaction within 6 days of vaccination and Grade of &gt;=1</description>
                <counts group_id="E1" subjects_affected="551" subjects_at_risk="616"/>
                <counts group_id="E2" subjects_affected="471" subjects_at_risk="606"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <description>Local Adverse Reaction occurring within 6 days of vaccination and a Grade of &gt;=1</description>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="540"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <description>Local event occurring within 6 days of vaccination and Grade of &gt;=1</description>
                <counts group_id="E1" subjects_affected="366" subjects_at_risk="609"/>
                <counts group_id="E2" subjects_affected="115" subjects_at_risk="599"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <description>Local Adverse Reaction occurring within 6 days of vaccination with Grade level &gt;=1</description>
                <counts group_id="E1" subjects_affected="392" subjects_at_risk="605"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="599"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <description>Local Adverse Reaction occurring within 6 days of vaccination with Grade level of &gt;=1</description>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="607"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="599"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="191" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="171" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="222" subjects_at_risk="610"/>
                <counts group_id="E2" subjects_affected="214" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="612"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="603"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="610"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="601"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tara Miller, Clinical Affairs Manager</name_or_title>
      <organization>PharmaJet, Inc.</organization>
      <phone>888-900-4321 ext 4163</phone>
      <email>tara.miller@pharmajet.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

